Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 10/20 | 0.49 |
| ▸ | HINT1 | P49773 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613722 | 0.80 | TYMP (0.55) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL8613718 | 0.80 | TYMP (0.55) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL34234 | 0.80 | TYMP (0.64) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL34927 | 0.80 | TYMP (0.64) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL21905183 | 0.79 | TYMP (0.57) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL1904550 | 0.79 | TYMP (0.76) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL10904155 | 0.79 | TYMP (0.76) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL35087 | 0.79 | TYMP (0.54) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL6869098 | 0.78 | TYMP (0.77) | TYMPHINT1GSK3ARPS6KA3MAPK14 | |
| SCHEMBL34560 | 0.77 | NT5E (0.39) | TYMPNT5EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188453-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | Cellsight Technologies Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022026533-A1 | METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING | CELLSIGHT TECHNOLOGIES INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20150118157-A1 | Compounds and Methods of Making Compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-30 | — | — | US | disclosed |
| US-9011817-B2 | Compounds and methods of making compounds | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118157-A1 | Compounds and Methods of Making Compounds | MCL1, TOP2B, TOP1 | TYMP 1956/4885HINT1 2653/4885GSK3A 2610/4885 |
| US-20210187133-A1 | Compounds and Methods of Making Compounds | MCL1, TOP1, TOP2B | TYMP 1765/4885HINT1 2568/4885GSK3A 2881/4885 |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | MCL1, TOP2B, TOP1 | TYMP 1956/4885HINT1 2653/4885GSK3A 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.